ClinicalTrials.gg
RecruitingNCT05531825Updated Sep 8, 2022

Clinical Evaluation Study of a Device for Detecting Arteriovenous Fistula Vascular Function

An observational study in Arteriovenous Fistula Flow Monitoring, Early Detection of Complications of Arteriovenous Fistula and Voiceprint, sponsored by Ai Peng. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-08.

Sponsored by Ai Peng · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 10 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.

Started
2022
with 1 other
Observational
6 of 20
2 open now
Registered
12th of 20
by date
Lead sponsor
2 of 20
Ai Peng

Among the 20 studies in Arteriovenous Fistula with a site in China, this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 12th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arteriovenous Fistula with a site in China, or all of them as a file.
02

Study summary

Evaluation on the reliability, practicability and safety of a wearable device for measuring arteriovenous fistula function based on voice print.

Read the detailed description

Arteriovenous fistula is the lifeline of maintenance hemodialysis patients. At present, there is a lack of a simple wearable real-time evaluation technology and device for arteriovenous fistula, which can help doctors find and deal with the complications of arteriovenous fistula timely and accurately. This study proposes an innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels, so that the use time of arteriovenous fistula can be prolonged and the survival rate of dialysis patients can also be improved.

03

Conditions studied

  • Arteriovenous Fistula Flow Monitoring
  • Early Detection of Complications of Arteriovenous Fistula
  • Voiceprint

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with end-stage renal disease undergoing or planning regular hemodialysis with autologous arteriovenous fistulas

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75.
  • Patients diagnosed with end-stage renal failure and planning to undergo venous fistula surgery or maintenance hemodialysis.
  • Sign the .

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women, bipolar disorder, schizophrenia and other serious mental illness.
  • Other circumstances deemed inappropriate by the researcher
  • Quit midway
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal control group

    Patients with no disease in the main organs, with well-developed body shape, and with good physiological functions, physical activity abilities and labor abilities.

    Device: A device for detecting arteriovenous fistula vascular function

  • Newly established arteriovenous fistula group

    Chronic kidney disease stage 5 (CKD5) non-dialysis patients planning to undergo internal arteriovenous fistula surgery.

    Device: A device for detecting arteriovenous fistula vascular function

  • reconstructed arteriovenous fistula group

    Patients with maintenance hemodialysis who need to reconstruct the internal arteriovenous fistula on account of dissatisfaction with blood flow.

    Device: A device for detecting arteriovenous fistula vascular function

  • Long-term maintenance hemodialysis group

    Patients undergoing hemodialysis with long-term fixed internal arteriovenous fistula.

    Device: A device for detecting arteriovenous fistula vascular function

Interventions

  • DeviceA device for detecting arteriovenous fistula vascular function

    An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels

06

What researchers measure

Primary outcomes

  1. Correlation between voiceprint spectrum and the blood flow of arteriovenous fistula

    Correlation between voiceprint spectrum and the blood flow of arteriovenous fistula

    Time frame: 2 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2022, 7 months after the start.

Of 34 observational studies under Arteriovenous Fistula, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 8, 2022
StartActual
May 1, 2022
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2025
Last update
Sep 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05531825
Lead sponsor
Ai Peng
Responsible party
Ai Peng (Director of the Department of Nephrology, Shanghai 10th People's Hospital) — Sponsor-investigator
First posted
Sep 8, 2022
Start date
May 1, 2022
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 8, 2022

Study contacts

Ai Peng, MD,PhD
Contact
pengai@tongji.edu.cn
86-21-66302524
Dayong Hu
Contact
shiyuanhudayong@sina.com
86-21-66302527
Ai Peng, MD,PhD
study director · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion